The news is all good this month. Here’s my M-protein level, which is a marker for the total cancer load in my bone marrow:

This is a significant drop, and I’m only through five weeks of an 8+8 chemo round (weekly for 8 weeks, then biweekly for 8 weeks). It’s almost certain to keep dropping over the next 11 weeks. And that’s not all:

The old chemo med compromised my immune system, and by the start of 2018 I was either at or below the danger level regularly. After I stopped that med and started the new one, my neutrophil level immediately jumped to around the 2000 level, which is perfectly healthy. That’s great news.

Considering all this, it’s worth explaining in a single place what’s going through my head these days. As I’ve mentioned, multiple myeloma is incurable. You can control it, but you can’t kill it off. Eventually it wins.

But not anymore. First of all, there are a bunch of new multiple myeloma drugs that hit the market a couple of years ago. The med I’m taking now is one of them. My first round of chemo lasted for about 3½ years, which isn’t bad, and there’s every reason to think the new drug will give me another two years. Then another will add a year or two to that. By the time I’ve worked my way through all the drugs that are likely to help, it’s now almost a dead certainty that a new form of treatment called CAR-T will be out of clinical trials and available to anyone who needs it (and who’s insured for the vast price it costs). There are several versions of CAR-T already available for other forms of cancer, and several that are in clinical trials for multiple myeloma. My current favorite is a Chinese treatment that was recently picked up by Johnson & Johnson for the North American market. The results so far have been pretty spectacular: a large share of patients appear to be in total remission, which is nearly unheard of. The side effects are sometimes painful, but they’re temporary (a few weeks) and doctors now know how to fight them.

Bottom line: Four years ago multiple myeloma was basically a death sentence. There was no telling how long it would take, but five years was average and ten was the outside range for 99 percent of patients. Today, it looks like I’ll end up going through five or ten years of various annoying rounds of chemo, and then stand a good chance of a total cure. I’ll still die eventually, just like everyone, but probably from tripping and falling down the stairs or something.

So that’s the story. Multiple myeloma is no fun, but I now fully expect a high chance of complete recovery. Thank you, medical researchers.


Headshot of Editor in Chief of Mother Jones, Clara Jeffery

It sure feels that way to me, and here at Mother Jones, we’ve been thinking a lot about what journalism needs to do differently, and how we can have the biggest impact.

We kept coming back to one word: corruption. Democracy and the rule of law being undermined by those with wealth and power for their own gain. So we're launching an ambitious Mother Jones Corruption Project to do deep, time-intensive reporting on systemic corruption, and asking the MoJo community to help crowdfund it.

We aim to hire, build a team, and give them the time and space needed to understand how we got here and how we might get out. We want to dig into the forces and decisions that have allowed massive conflicts of interest, influence peddling, and win-at-all-costs politics to flourish.

It's unlike anything we've done, and we have seed funding to get started, but we're looking to raise $500,000 from readers by July when we'll be making key budgeting decisions—and the more resources we have by then, the deeper we can dig. If our plan sounds good to you, please help kickstart it with a tax-deductible donation today.

Thanks for reading—whether or not you can pitch in today, or ever, I'm glad you're with us.

Signed by Clara Jeffery

Clara Jeffery, Editor-in-Chief

payment methods

We Recommend